Chosa Oncology, Danish -Swedish biotechnology company, has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the companion diagnostic (DRP) tool detecting patients who benefits the most of the cisplatin treatment. The recently achieved clinical phase 2b results mean that the Company is now gearing up the business development activities to find partners for partnership or trade deal.

Quotes for CHOSA Oncology AB

Right Now

+/-
0.11
%
12,53%
Latest
0.988
High
1.09
Low
0.878
Volume
87 983
Turnover (SEK)
81 081
Market Value (MSEK)
70,1
Time (Latest trade)

Board

CEO

  • Peter Buhl

Chairperson of the Board

  • Lars Hedbys

Board

  • Claus Frisenberg Pedersen
  • Ingrid Atteryd Heiman
  • Lars Hedbys
  • Neil Goldsmith
  • Ulla Hald Buhl

Largest Owners

Name Capital % Votes % Date
Buhl Krone Holding ApS 22,00 22,00 2024-06-26
Claus Frisenberg Pedersen 11,68 11,68 2023-01-18
IPO Nordic Fund A/S 8,36 8,36 2024-06-26
Smerud Medical Research International AS 7,48 7,48 2024-06-26
Rutger Arnhult 5,48 5,48 2024-06-26
Nels Holding Aps 4,03 4,03 2024-06-26
Lh|Lh Invest Aps 2,97 2,97 2024-06-26
Karsgaard Holding Ostervra Aps 2,36 2,36 2024-06-26
Sorgenfri Nr. 1 A/S 1,97 1,97 2024-06-26
Rq Solutions Aps 1,87 1,87 2024-06-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream